Tigecycline is a last-resort antibiotic that is used to treat severe infections caused by extensively drug-resistant bacteria. However, the efficacy and safety data for tigecycline in infectious patients are lacking. The aim of this study is to assess the efficacy and safety of tigecycline in infectious patients using pharmacokinetics and omics.
Study Type
OBSERVATIONAL
Enrollment
300
Efficacy and safety of Tigecycline
Wei Zhao
Jinan, Shandong, China
RECRUITINGAdverse events
Drug-related adverse events and serious adverse events
Time frame: Through study completion, an average of 15 days
Pharmacokinetics of tigecycline
clearance in L/h
Time frame: Through study completion, an average of 3 days
Rate constant for tigecycline distribution
Pharmacokinetics of tigecycline
Time frame: Through study completion, an average of 3 days
The ratio of area under the concentration-time curve (AUC) to minimum inhibitory concentration (MIC).
PD target
Time frame: Through study completion, an average of 3 days
fibrinogen levels in mg/dL
Time frame: Through study completion, an average of 3 days
prothrombin time
prothrombin time in second
Time frame: Through study completion, an average of 3 days
activated partial thromboplastin time
activated partial thromboplastin time in second
Time frame: Through study completion, an average of 3 days
international normalized ratio
international normalized ratio，INR
Time frame: Through study completion, an average of 3 days
blood platelet count
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
blood platelet count in ×10\^9/L
Time frame: Through study completion, an average of 3 days
thrombin time
thrombin time in second
Time frame: Through study completion, an average of 3 days